Scope
NICE guideline NG219 (2022) covers the diagnosis and management of gout. It sets out clinical features that should prompt suspicion of gout and how to assess for alternative causes. It covers serum urate testing, joint aspiration and imaging. It addresses patient information, diet and lifestyle, and first-line and escalation treatment of flares. For long-term care it covers eligibility for urate-lowering therapy (ULT), treat-to-target titration and serum urate targets, and the choice between allopurinol and febuxostat. It also covers prophylaxis against flares during ULT initiation or titration, monitoring, and referral to rheumatology. Recommendation wording distinguishes actions to offer from options to consider.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognition, assessment and diagnosis
- Suspect gout when there is rapid-onset severe pain with redness and swelling in one or both first MTP joints, or when tophi are present. [1]
- Consider gout when similar rapid-onset severe pain, redness or swelling affects other joints, such as the midfoot, ankle, knee, hand, wrist or elbow. Consider chronic gouty arthritis in chronic inflammatory joint pain. In suspected gout, take a detailed history and examine the patient. [1]
- In anyone with a painful, red, swollen joint, assess for septic arthritis, calcium pyrophosphate crystal deposition and inflammatory arthritis. If septic arthritis is suspected, refer immediately via the local care pathway. [1]
- Measure serum urate to confirm a clinical diagnosis; a level of 360 micromol/litre (6 mg/dl) or more supports it. If the level is lower during a flare but gout is strongly suspected, repeat the test at least 2 weeks after the flare settles. [1]
- If the diagnosis remains uncertain or unconfirmed, consider joint aspiration with synovial fluid microscopy. If aspiration is not possible or uncertainty persists, consider X-ray, ultrasound or dual-energy CT of the affected joints. [1]
Information, support, diet and lifestyle
- At diagnosis and at follow-up, give tailored information to patients and, where appropriate, their family or carers. Cover: - the symptoms and causes of gout; - progression without intervention; - personal risk factors, such as weight, medicines, CKD or hypertension; - flare management; - gout as a lifelong condition that benefits from long-term ULT; - sources of support. [1]
- Explain that evidence is insufficient to show that any specific diet prevents flares or lowers urate, and advise a healthy, balanced diet. Advise that excess weight, obesity or excessive alcohol may worsen flares and symptoms. [1]
Managing gout flares
- Offer an NSAID, colchicine or a short oral corticosteroid course first-line, guided by comorbidities, co-prescriptions and preference. Oral corticosteroid use for this indication was off-label in June 2022. [1]
- Consider adding a proton pump inhibitor when an NSAID is used for a flare. [1]
- Consider an intra-articular or intramuscular corticosteroid injection if NSAIDs and colchicine are contraindicated, not tolerated or ineffective. This was off-label in June 2022. [1]
- Do not offer an IL-1 inhibitor for a flare unless NSAIDs, colchicine and corticosteroids are all contraindicated, not tolerated or ineffective. Refer to rheumatology before prescribing one. [1]
- Advise that ice packs on the affected joint, alongside prescribed medicine, may help relieve pain. [1]
- Consider a follow-up appointment once the flare settles to: - measure serum urate; - give self-management information; - assess lifestyle and comorbidities, including cardiovascular risk and CKD; - review medicines and discuss long-term ULT. [1]
Long-term urate-lowering therapy
- Offer treat-to-target ULT to people with any of the following: - multiple or troublesome flares; - CKD stages 3 to 5 (GFR G3 to G5); - diuretic therapy; - tophi; - chronic gouty arthritis. [1]
- For other patients after a first or subsequent flare, discuss treat-to-target ULT as an option. Make sure patients understand that ULT usually continues after the target is reached and is typically lifelong. [1]
- Start ULT at least 2 to 4 weeks after a flare has settled. When flares are more frequent, ULT can be started during a flare. [1]
- Begin at a low dose and increase as tolerated, guided by monthly serum urate measurements, until the target is achieved. [1]
- Target serum urate below 360 micromol/litre (6 mg/dl). Consider a lower target, below 300 micromol/litre (5 mg/dl), for people with tophi or chronic gouty arthritis. Also consider it for people with frequent flares despite urate below 360 micromol/litre. [1]
- Offer allopurinol or febuxostat first-line, based on comorbidities and preference. In major cardiovascular disease, such as previous myocardial infarction or stroke, or unstable angina, offer allopurinol first-line. [1]
- If the target is not reached or first-line treatment is not tolerated, consider switching to allopurinol or febuxostat as second-line treatment. [1]
- Discuss the benefits and risks of flare prophylaxis during ULT initiation or titration. For those who choose it, offer colchicine until the target is reached. If colchicine is contraindicated, not tolerated or ineffective, consider a low-dose NSAID or low-dose oral corticosteroid; these were off-label in June 2022. Consider adding a PPI with an NSAID or corticosteroid, taking individual adverse-event risk into account. [1]
- Do not offer an IL-1 inhibitor for flare prophylaxis during ULT unless colchicine, NSAIDs and corticosteroids are contraindicated, not tolerated or ineffective. Refer to rheumatology before prescribing one. [1]
- Once the target is reached and ULT continues, consider annual serum urate monitoring. [1]
Referral to specialist services
- Consider rheumatology referral if: - the diagnosis is uncertain; - treatment is contraindicated, not tolerated or ineffective; - the patient has CKD stages 3b to 5 (GFR G3b to G5); - the patient has had an organ transplant. [1]
Limitations and use
- Summary is based on the recommendations chapter only. The following were excluded from the source and not reviewed: research recommendations, rationale and impact, update history, committee information, and the evidence reviews and committee discussion.
- Linked flowcharts and visual algorithms were not available beyond any alternative text.
- The guideline gives no specific drug doses or titration increments for allopurinol, febuxostat, colchicine, NSAIDs or corticosteroids. Off-label status is stated as at June 2022.
- Related guidance referenced by the guideline is not summarised here. This includes guidance on patient experience, shared decision making, medicines adherence, CKD, cardiovascular disease and obesity.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Gout: diagnosis and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 9 June 2022
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.